BMY News 50.99 04/22/2014 17:28:05 Bristol-Myers Squibb Company

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bristol-Myers Squibb Company (BMY) 50.99 $BMY

Final Glance: Pharmaceuticals companies
AP - 25 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Midday Glance: Pharmaceuticals companies
AP - Tue Apr 22, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Global Synthetic Biology Market 2013-2019 - Genome Engineering, DNA Sequencing, Bioinformatics & Biological Components and Integrated Systems
M2 - Tue Apr 22, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/29nxfg/synthetic_biology) has announced the addition of the "Synthetic Biology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019" report to their offering. Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years. Synthetic biology market by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market. Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period. The global synthetic biology market is segmented into the following categories: Products - Core Products - - Synthetic DNA - - Synthetic Genes - - Synthetic Cells - - XNA (Xeno Nucleic Acid) - - Chasis Organisms - Enabling Products - - DNA Synthesis - - Oligonucleotide Synthesis Technologies - Genome Engineering - DNA Sequencing - Bioinformatics - Biological Components and Integrated Systems Applications - Healthcare - Chemicals (Including Bio-Fuels) - Agriculture - Others (Biosecurity, R&D, Energy and Environment) Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Synthetic Biology Market, by Products - Global Synthetic Biology Market, by Technologies - Global Synthetic Biology Market, by Applications - Global Synthetic Biology Market, by Geography - Competitive Landscape - Recommendations - Company Profiles - Agrivida, Inc. - Amyris, Inc. - Algenol Biofuels, Inc. - ATG:biosynthetics GmbH - Bayer AG - Bristol-Myers Squibb - BIONEER CORPORATION - Biosearch Technologies, Inc. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - DuPont, Inc. - Evolva SA - Exxon Mobil Corporation - Ginkgo Bioworks - GeneWorks Pty Ltd. - Genomatica, Inc. - GeneScript Corporation - Gevo, Inc. - Green Biologics Limited - New England Biolabs, Inc. - OriGene Technologies, Inc. - REG Life Sciences, LLC - Royal DSM - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/29...ic_biology

Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...

SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 2.12% Gain
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:45PM CDT
Share price of Galectin Therapeutics jumped 12.9% after the company announced dosing of the first patient in cohort 2 of a phase I study on GR-MD-02.

Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...

Bristol-Myers Squibb (BMY) Breaks Through Resistance at $49.78
Comtex SmarTrend(R) - Mon Apr 21, 11:44AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $49.36 today and has reached the first level of resistance at $49.78. Should the shares continue to rise, the resistance pivots of $50.09 and $50.82 will be of interest.

Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...

Early Glance: Pharmaceuticals companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:

Would Pfizer Buying AstraZeneca Actually Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 9:03AM CDT
Mondays are commonly referred to as "Merger Mondays" for a reason: the weekend gives companies time to hash out deals without the overbearing scrutiny of Wall Street analysts and investors who are also off for the weekend. Although no such deal was...

If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...

Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
PR Newswire - Thu Apr 17, 10:30AM CDT
Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use Bayer/Janssen's Xarelto in 14 percent and 31 percent of their patients respectively, with over two-thirds of surveyed physicians increasing their use of Xarelto by 2015. Physicians indicate that Bristol-Myers Squibb/Pfizer's Eliquis is expected to garner a 19 percent patient share in 2015. Use of Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Savaysa are also expected to garner double-digit patient share in 2015, despite the requirement for preceding use of an injectable anticoagulant.

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences '  freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...

2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials  has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 92

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 52

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 89

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 81

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 43

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 67

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading

Top 5 Most Recently Viewed Articles

PAPZIMEOS Emerges as the Go-To Treatment for RRP Patients

Updated Category News Views 104

PAPZIMEOS: A Promising New Standard for RRP Therapy PAPZIMEOS (zopapogene imadenovec) has gained recognition as an innovative treatment for adults suffering from recurrent respiratory papillomatosis (RRP). This breakthrough comes following the publication of a consensus paper authored by 16 leading experts in the field. Sponsored by the Recurrent Respiratory...

Continue Reading
Ollie's Bargain Outlet Reports Encouraging Q2 Results

Updated Category News Views 159

Ollie's Bargain Outlet Achieves Strong Q2 Performance Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has made headlines recently as its shares experience fluctuations in the market. The company revealed impressive second-quarter adjusted earnings per share of 99 cents, surpassing analyst expectations of 94 cents. The quarterly sales reached $679.556 million, marking...

Continue Reading
Fivecast Introduces Groundbreaking Discovery Solution for OSINT

Updated Category News Views 184

Fivecast Unveils Discovery Solution to Combat Global Threats In today's rapidly evolving landscape of global threats, Fivecast, a prominent provider of advanced open-source intelligence (OSINT) solutions, has rolled out an innovative Discovery solution designed to assist analysts and investigators in both government and corporate settings. By elevating the speed and...

Continue Reading
Zen Technologies USA Advances Military Training with AI Simulations

Updated Category News Views 224

Zen Technologies USA Showcases Cutting-Edge AI Simulations Zen Technologies USA is set to revolutionize military training capabilities with its next-generation AI-enabled live and virtual simulation solutions. By enabling high-fidelity training for ground and naval forces, these innovations aim to accelerate the readiness of military units while significantly reducing...

Continue Reading
Sectra and Siemens Healthineers Transform Radiology Workflows

Updated Category News Views 494

Revolutionizing Radiology with Innovative Integrations International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG have formed a pivotal collaboration aimed at enhancing diagnostic capabilities in the radiology field. This initiative seeks to improve patient care by enabling seamless access to advanced imaging technologies....

Continue Reading